Phase 3
N=315
Gadobutrol Enhanced MRA of the Renal Arteries
Renal Artery Obstruction
Bottom Line
View on ClinicalTrials.gov: NCT01344460 ↗Enrolled (actual)
315
Serious AEs
0.0%
Results posted
Aug 2015
Primary outcome: Primary: Percentage of Assessable Vascular Segments Using Gadobutrol-Enhanced MRA and Unenhanced MRA — 95.9; 77.6; 98.1; 81.7 Percentage of segments — p=<0.000
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Gadobutrol (Gadovist, BAY86-4875) (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Bayer
- Primary completion
- Jul 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Assessable Vascular Segments Using Gadobutrol-Enhanced MRA and Unenhanced MRA |
95.9; 77.6; 98.1; 81.7; 95.5; 71.5 | <0.000 sig |
| PRIMARY Sensitivity for Detection of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA |
53.4; 46.6; 51.9; 51.1; 54.1; 39.1 | — |
| PRIMARY Specificity for Exclusion of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA |
94.8; 85.7; 94.4; 83.1; 94.8; 85.0 | — |
| PRIMARY Minimum Gadobutrol Performance for Sensitivity: Sensitivity More Than (>) 50% |
54.6; 51.6; 54.4; 53.4; 71.3 | — |
| PRIMARY Minimum Gadobutrol Performance for Specificity: Specificity > 50% |
95.9; 95.0; 96.2; 95.8; 98.4 | — |
| SECONDARY Length of the Right and Left Renal Arteries Assessed by Gadobutrol-enhanced MRA and Unenhanced MRA - Blinded Reader |
35.07; 32.25; 46.23; 43.05; 35.07; 32.15 | — |
| SECONDARY Length of the Right and Left Renal Arteries Assessed by Computed Tomographic Angiography (CTA) - Blinded Reader |
36.59; 48.44; 36.59; 48.44; 36.59; 48.45 | — |
| SECONDARY Vessel Diameter (Millimeter [mm]) at the Normal Point and the Narrowest Point in Gadobutrol-Enhanced MRA, Unenhanced MRA and CTA Images |
5.13; 4.83; 5.08; 2.80; 2.30; 2.80 | — |
| SECONDARY The Percentage of Location of Stenosis >= 50% (Within and Beyond 5 Millimeter From the Aorta) in the Proximal Segments Assessed by Gadobutrol-Enhanced MRA and Unenhanced MRA |
26.4; 22.9; 73.5; 71.8; 25.3; 21.8 | — |
| SECONDARY The Percentage of Segments With Artifacts Presence |
24.7; 92.3; 22.1; 80.4; 41.5; 97.4 | — |
| SECONDARY Types of Artifacts Assessed by Gadobutrol-enhanced MRA and Unenhanced MRA by Blinded Reader 1 |
17.5; 81.4; 4.8; 15.1; 0.2; 0.4 | — |
| SECONDARY Types of Artifacts Assessed by Gadobutrol-enhanced MRA and Unenhanced MRA by Blinded Reader 2 |
5.4; 57.1; 12.0; 9.6; 0.2; 24.4 | — |
| SECONDARY Types of Artifacts Assessed by Gadobutrol-enhanced MRA and Unenhanced MRA by Blinded Reader 3 |
32.8; 96.2; 14.2; 34.5; 3.0; 56.0 | — |
| SECONDARY The Percentage of Accessory (Non-dominant) Renal Artery Presence Assessed by Gadobutrol-Enhanced MRA and Unenhanced MRA |
7.2; 0.7; 9.2; 1.4; 15.4; 2.7 | — |
| SECONDARY The Presence of Any Aneurysmal Dilatation in Each Segment (Proximal, Mid- and Distal) in the Right and the Left Renal Arteries Assessed by Gadobutrol-Enhanced MRA and Unenhanced MRA |
0.3; 0; 1.0; 0; 1.4; 0 | — |
| SECONDARY The Percentage of Participants With Diagnosis of Fibromuscular Dysplasia and Arteriosclerosis Assessed by Gadobutrol-Enhanced MRA and Unenhanced MRA |
2.7; 0.7; 16.4; 12.0; 4.1; 0.0 | — |
| SECONDARY Diagnostic Confidence by the Blinded Readers Using Gadobutrol-Enhanced MRA and Unenhanced MRA |
3.0; 1.9; 3.5; 2.1; 3.5; 2.2 | — |
| SECONDARY The Percentage of Participants With Additional Imaging Studies Recommended by the Blinded Readers and the Clinical Investigator After Evaluation of the Gadobutrol-Enhanced and Unenhanced MRA Images |
41.4; 96.6; 14.0; 77.1; 8.6; 44.9 | — |
| SECONDARY Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Gadobutrol-Enhanced and Unenhanced MRA Images - Blinded Reader 1 |
0; 2; 1; 0; 120; 280 | — |
| SECONDARY Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Gadobutrol-Enhanced and Unenhanced MRA Images - Blinded Reader 2 |
0; 0; 0; 114; 39; 110 | — |
| SECONDARY Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Gadobutrol-Enhanced and Unenhanced MRA Images - Blinded Reader 3 |
0; 1; 1; 14; 22; 116 | — |
| SECONDARY Types of Additional Imaging Studies Recommended by the Clinical Investigator After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images |
0; 0; 2; 114; 50; 12 | — |
Summary
Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days. Two to three visits to the study doctor will be required.
This study will compare the diagnostic results of Gadobutrol enhanced MRA images with MRA images taken without contrast agent using images from a CTA as the standard of reference, which may have been performed up to 60 days prior to enrolment. If a CTA has not been performed in this prior time period, a CTA is required for the study.
MRA and CTA images will be collected for an independent review (blinded read).
Eligibility Criteria
Inclusion Criteria
- Male or female subjects, aged ≥ 18 years
- Known or suspected renal artery disease based on any of the following:
- Referred for evaluation of the renal arteries for clinically significant stenosis
- Follow-up for a metallic stent in a renal artery
- Prior imaging study (CTA) showing ≥ 50% renal artery stenosis (within 60 days prior to consent)
- Willingness to undergo the routine Contrast Enhanced Magnetic Resonance Angiography (CE MRA) examinations with gadobutrol.
- Willingness and ability to follow directions and complete all study procedures specified in the protocol.
- Females of childbearing potential only: Negative pregnancy test on the day of the MRA prior to administration of study drug.
- Written informed consent (IC), including information about the provisions of the Health Insurance Portability and Accountability Act (HIPAA) as applicable.
Exclusion Criteria
- Pregnant or nursing (including pumping for storage and feeding)
- Received any other investigational product or participation in any other clinical trial within 30 days before enrollment into this study
- Previous enrolment into this study or into any other Bayer sponsored study using gadobutrol
- Contraindication to the MRA examinations (e.g. inability to hold breath; severe arrhythmias; very low cardiac output, severe claustrophobia, defibrillators or other metallic devices not approved for MRI)
- Contraindication to the use of Gd-containing contrast agents (including subjects with suspicion for or known to have Nefrogenic Systemic Fibrosis (NSF)
- History of severe allergic or anaphylactoid reaction to any allergen including drugs and contrast agents
- Received any contrast agent within 72 hours before the study MRA, or scheduled receipt of any contrast agent within 24 hours after the study MRA (Note: This applies also to a CTA potentially scheduled during the course of the study.)
- Estimated glomerular filtration rate (eGFR) value < 30 ml/min/1.73 m2 derived from a serum creatinine result within 2 weeks before the gadobutrol injection. Any subject on hemodialysis or peritoneal dialysis is excluded from participation. Use the value obtained prior to and closest to the time of the MRA, if there are multiple creatinine values. (Do not use the core lab value if not available prior to the MRA.)
- Acute renal insufficiency of any intensity, either due to hepato-renal syndrome or occurring in the peri-operative liver transplantation period
- Severe cardiovascular disease (e.g. acute myocardial infarction [< 14 days], unstable angina, congestive heart failure New York Heart Association class IV) or known long QT syndrome
Data sourced from ClinicalTrials.gov (NCT01344460). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.